Health sector stocks fluctuate amid DOJ probe into UnitedHealth (UNH), Gilead upgrade for HIV treatments, and Moderna's focus on non-COVID approvals.
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
MarketBeat on MSN1d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Key Takeaways Salesforce plans to report fourth-quarter results after the closing bell Wednesday.A majority of analysts ...
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
This was the stock's third consecutive day of gains.
While recruitment and regulation are improving, they remain pain points, say speakers at Arena International’s OCT West Coast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback